CMT1A
CMT1A, the most common type of CMT, is caused by an extra copy (duplication) of the PMP22 gene. More in the glossary
-
·
Canada’s CMT1A Research Partnership: Who Funds It, and Who Gets the Rights?
The NRC, CMTA, and Shark Tooth Biotech are pursuing an experimental CMT1A delivery approach. Disclosed investments raise questions about research contributions, commercial rights and benefits for Canada. The partners’ responses and the unanswered questions are set out here.
-
·
Plain-Language Research Summary: A Blood Test for Nerve-Fibre Loss in CMT
A 2025 study found the nerve-damage protein NfL more than twice as high in the blood of people with CMT, and loosely linked to severity. What it shows, what it can’t, and how it fits with earlier studies.
-
·
Shark Tooth: The CMTA’s Stake in a Board Member’s Biotech
In 2025 the CMTA held a $248,763 stake in a for-profit CMT1A company founded and owned by one of its own directors, built from donations earmarked for it. The audit says that director recused himself. A policy for its grant advisers leaves other conflicts to the chief executive.
-
·
Three “Treatable CMT” Stories, and What the Market Taught Us
Three heavily publicized CMT treatments of 2019–2023 (govorestat, PXT3003, and Engensis) all ended without a CMT approval, and the way they ended says a lot about how drug development treats rare neuropathies.
-
·
CIDP and CMT
CIDP and CMT can be mistaken for each other, especially demyelinating CMT1. How often misdiagnosis happens, and why it matters since CIDP is treatable.
-
·
If Pain Makes You Avoid Exercise, You’ll Gain More of It
A study of people with CMT who exercised at least once a week (mostly gym workouts) for at least six months found their pain levels were noticeably lower than in a group that didn’t exercise, and their quality-of-life scores were better. Depression scores did not differ significantly, and the study can’t show that exercise caused…
-
·
Physical Assessments for CMT
There are several validated assessment instruments for CMT to take stock of its current and later states of progression.
-
·
All types of CMT are “Axonal”
CMT1 types have commonly been referred to as “demyelinating” and CMT2 as “axonal,” which gives the impression the nature of the nerve damage between the two is fundamentally different.
-
·
Maybe it will work on CMT..?
It seems the new hope for VM202 as a CMT1A treatment is perhaps Helixmith’s latest attempt to find a market for an experimental product that has not panned out as hoped.
-
·
Nerve Tests Don’t Predict Quality of Life in CMT1A
In a study of adults with CMT1A, severe nerve-test results didn’t match up with quality of life, independence, or hand function. Nerve conduction tests say little about how you’re actually living with CMT.
-
·
Genetic Cause of CMT2 Discovered?
A 2020 study linked JAG1 mutations to axonal CMT2 in two families. Updated in 2026: JAG1-related CMT now has its own OMIM entry, CMT2HH.
-
·
CMT and Respiratory Dysfunction
Science is starting to confirm very wide ranging effects to the nerve damage CMT does, often slowly and over time so it may not be very noticeable for many years.